ADVERTISEMENT

Eris Lifesciences Q1 Results Review - Inline; Strong Start To Business Integration: Prabhudas Lilladher

The brokerage expects margins to sustain at +35% as revenue scales up from recent acquisitions which is currently operating at sub optimal profitability.

<div class="paragraphs"><p>Medicines. (Source: Milivigerova/ pexels)</p></div>
Medicines. (Source: Milivigerova/ pexels)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More